# US 2002/0165159 A1 · FSH-releasing peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0165159 A1
- Document ID: US20020165159A1
- Status: Published application
- Kind: A1
- Application number: 10/109,331
- Filed: 2002-03-28
- Published: 2002-11-07
- Earliest claimed: 1997-06-04
- Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
- Inventors: Samuel M. McCann; Wen H. Yu
- Web page: https://patentgrep.com/patent/US20020165159A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- C07K 7/23: Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Lamprey LHRH-III is a potent FSH-releasing factor, and may be used to enhance fertility. Antagonists to lamprey LHRH-III may be used to inhibit fertility.

## Claims

### Claim 1

A method of altering the level of secretion of FSH in a vertebrate animal, comprising administering to the animal an effective amount of a peptide selected from the group consisting of an l-LHRH-III agonist peptide; an l-LHRH-III superagonist peptide; an l-LHRH-III antagonist peptide; a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41; and l-LHRH-III (SEQ. ID NO. 1); wherein the amount of the peptide administered causes a selective change in the serum FSH level of the animal, but does not cause a proportional change in the serum LH level of the animal.

### Claim 2 (depends on 1)

A method as recited in claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of l-LHRH-III (SEQ. ID No. 1).

### Claim 3 (depends on 2)

A method as recited in claim 2, wherein the animal is a mammal.

### Claim 4 (depends on 3)

A method as recited in claim 3, wherein the animal is a human.

### Claim 5 (depends on 4)

A method as recited in claim 4, wherein the human is male.

### Claim 6 (depends on 4)

A method as recited in claim 4, wherein the human is female.

### Claim 7 (depends on 2)

A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of claim 2.

### Claim 8 (depends on 7)

A method as recited in claim 7, wherein the animal is a mammal.

### Claim 9 (depends on 8)

A method as recited in claim 8, wherein the animal is a human.

### Claim 10 (depends on 9)

A method as recited in claim 9, wherein the human is male.

### Claim 11 (depends on 9)

A method as recited in claim 9, wherein the human is female.

### Claim 12 (depends on 1)

A method as recited in claim 1, wherein the level of secretion of FSH in the animal is increased; said method comprising administering to the animal an effective amount of an l-LHRH-III agonist peptide or l-LHRH-III superagonist peptide; wherein the amount of the peptide administered causes a selective increase in the serum FSH level of the animal, but does not cause a proportional increase in the serum LH level of the animal.

### Claim 13 (depends on 12)

A method as recited in claim 12, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of l-LHRH-III (SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or
(b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of l-LHRH-III is deleted.

### Claim 14 (depends on 13)

A method as recited in claim 13, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.

### Claim 15 (depends on 12)

A method as recited in claim 12, wherein the animal is a mammal.

### Claim 16 (depends on 15)

A method as recited in claim 15, wherein the animal is a human.

### Claim 17 (depends on 16)

A method as recited in claim 16, wherein the human is male.

### Claim 18 (depends on 16)

A method as recited in claim 16, wherein the human is female.

### Claim 19 (depends on 12)

A method of increasing the fertility of a vertebrate animal, comprising increasing the level of FSH secretion in the animal by the method of claim 12.

### Claim 20 (depends on 19)

A method as recited in claim 19, wherein the peptide is selected from the group consisting of decapeptides whose sequences are identical to the sequence of l-LHRH-III (SEQ. ID NO. 1), except that either or both of the following conditions is satisfied:
(a) the sixth amino acid residue is a natural or xenobiotic amino acid residue other than aspartic acid; or
(b) the ninth amino acid residue is prolyl ethyl amide (ProNHEt); and the tenth amino acid residue of l-LHRH-III is deleted.

### Claim 21 (depends on 20)

A method as recited in claim 20, wherein the peptide is selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.

### Claim 22 (depends on 19)

A method as recited in claim 19, wherein the animal is a mammal.

### Claim 23 (depends on 19)

A method as recited in claim 19, wherein the animal is a human.

### Claim 24 (depends on 23)

A method as recited in claim 23, wherein the human is male.

### Claim 25 (depends on 23)

A method as recited in claim 23, wherein the human is female.

### Claim 26 (depends on 1)

A method as recited in claim 1, wherein the level of secretion of FSH in the animal is decreased; said method comprising administering to the animal an effective amount of an l-LHRH-III antagonist peptide; wherein the amount of the peptide administered causes a selective decrease in the serum FSH level of the animal, but does not cause a proportional decrease in the serum LH level of the animal.

### Claim 27 (depends on 26)

A method as recited in claim 26, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.

### Claim 28 (depends on 26)

A method as recited in claim 26, wherein the animal is a mammal.

### Claim 29 (depends on 28)

A method as recited in claim 28, wherein the animal is a human.

### Claim 30 (depends on 29)

A method as recited in claim 29, wherein the human is male.

### Claim 31 (depends on 29)

A method as recited in claim 29, wherein the human is female.

### Claim 32 (depends on 26)

A method of decreasing the fertility of a vertebrate animal, comprising decreasing the level of FSH secretion in the animal by the method of claim 26.

### Claim 33 (depends on 32)

A method as recited in claim 32, wherein the antagonist is selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.

### Claim 34 (depends on 32)

A method as recited in claim 32, wherein the animal is a mammal.

### Claim 35 (depends on 34)

A method as recited in claim 34, wherein the animal is a human.

### Claim 36 (depends on 35)

A method as recited in claim 35, wherein the human is male.

### Claim 37 (depends on 35)

A method as recited in claim 35, wherein the human is female.

### Claim 38

A composition selected from the group consisting of an l-LHRH-III agonist peptide; an l-LHRH-III superagonist peptide; an I-LHRH-III antagonist peptide; a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 41; and an effective amount of substantially pure l-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier; wherein said composition has the property that said composition will, when administered in an effective amount to a vertebrate animal, cause a selective change in the serum FSH level of the animal, but will not cause a proportional change in the serum LH level of the animal.

### Claim 39 (depends on 38)

A composition as recited in claim 38, wherein said composition comprises an effective amount of substantially pure l-LHRH-III (SEQ. ID NO. 1) admixed with a pharmaceutically acceptable carrier.

### Claim 40 (depends on 38)

A composition as recited in claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 6 through SEQ. ID NO. 32.

### Claim 41 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 6.

### Claim 42 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 7.

### Claim 43 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 8.

### Claim 44 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 9.

### Claim 45 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 10.

### Claim 46 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 11.

### Claim 47 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 12.

### Claim 48 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 13.

### Claim 49 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 14.

### Claim 50 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 15.

### Claim 51 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 16.

### Claim 52 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 17.

### Claim 53 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 18.

### Claim 54 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 19.

### Claim 55 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 20.

### Claim 56 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 21.

### Claim 57 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 22.

### Claim 58 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 23.

### Claim 59 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 24.\

### Claim 60 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 25.

### Claim 61 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 26.

### Claim 62 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 27.

### Claim 63 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 28.

### Claim 64 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 29.

### Claim 65 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 30.

### Claim 66 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 31.

### Claim 67 (depends on 40)

A peptide as recited in claim 40, wherein said peptide is SEQ. ID NO. 32.

### Claim 68 (depends on 38)

A composition as recited in claim 38, wherein said composition comprises a peptide selected from the group consisting of SEQ. ID NO. 33 through SEQ. ID NO. 41.

### Claim 69 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 33.

### Claim 70 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 34.

### Claim 71 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 35.

### Claim 72 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 36.

### Claim 73 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 37.

### Claim 74 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 38.

### Claim 75 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 39.

### Claim 76 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 40.

### Claim 77 (depends on 68)

A peptide as recited in claim 68, wherein said peptide is SEQ. ID NO. 41.
